Pular para o conteúdo
Merck
  • Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis.

Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis.

Journal of immunology (Baltimore, Md. : 1950) (2007-12-22)
Itay Shalev, Hao Liu, Cheryl Koscik, Agata Bartczak, Mojib Javadi, Kit Man Wong, Asif Maknojia, Wei He, Ming Feng Liu, Jun Diao, Erin Winter, Justin Manuel, Doug McCarthy, Mark Cattral, Jennifer Gommerman, David A Clark, M James Phillips, Reginald R Gorczynski, Li Zhang, Greg Downey, David Grant, Myron I Cybulsky, Gary Levy
RESUMO

Mice with targeted deletion of fibrinogen-like protein 2 (fgl2) spontaneously developed autoimmune glomerulonephritis with increasing age, as did wild-type recipients reconstituted with fgl2-/- bone marrow. These data implicate FGL2 as an important immunoregulatory molecule and led us to identify the underlying mechanisms. Deficiency of FGL2, produced by CD4+CD25+ regulatory T cells (Treg), resulted in increased T cell proliferation to lectins and alloantigens, Th 1 polarization, and increased numbers of Ab-producing B cells following immunization with T-independent Ags. Dendritic cells were more abundant in fgl2-/- mice and had increased expression of CD80 and MHCII following LPS stimulation. Treg cells were also more abundant in fgl2-/- mice, but their suppressive activity was significantly impaired. Ab to FGL2 completely inhibited Treg cell activity in vitro. FGL2 inhibited dendritic cell maturation and induced apoptosis of B cells through binding to the low-affinity FcgammaRIIB receptor. Collectively, these data suggest that FGL2 contributes to Treg cell activity and inhibits the development of autoimmune disease.